Angelini Pharma has announced that it is buying Catalyst Pharmaceuticals. for $31.50 per share in cash — for a total of approximately $4.1 billion — in a move that will strengthen its position as industry leader in brain health and rare diseases.
Catalyst is a commercial-stage biopharmaceutical company with a focus on novel medicines for rare neuromuscular and neurological diseases. Its portfolio includes the oral drug Firdapse (amifampridine), the only FDA approved treatment for Lambert-Eaton myasthenic syndrome (LEMS).
Angelini is an international pharmaceutical company and part of the 100-year-old Angelini Industries Group. Its purchase of Catalyst will allow it to enter the U.S. market. The deal is expected to close in Q3 2026. Upon completion, Angelini Pharma plans to develop a next-generation rare diseases platform by combining Catalyst’s products and commercial infrastructure with its own portfolio and expertise.